* From HemOnc Today, March 10, 2013, Page 29. [Gastrointestinal Cancer Symposium, San Francisco. Jan 24-26, 2013] “Docetaxel extended OS for patients with relapsed esophago-gastric cancers” Written by Anthony Calabro. …Approxomately 39,000 new cases of esophago-gastric cancers are diagnosed in the United States each year, and current treatments are associated with poor outcomes…In the current multicenter, open-label, randomized controlled trial, Ford and colleagues enrolled 168 patients with locally advanced or metastatic esophago-gastric adenocarcinoma whose disease progressed within 6 months of initial chemotherapy. Patients assigned to docetaxel experienced significantly longer median OS (5.2 months vs. 3.6 months;). In that trial, there are twenty-one percent of patients assigned to docetaxel experienced Grade 4 toxicity. This study was not clear to me is that we don’t know how many locally advanced cancer patients were assigned in the experimental arm. Since it is a open-label trial, how did they random patients? Compared with Lisha Fan MD’s therapy, their results are inferior to mine in Four aspects – OS, QOL, Toxicity and Cost, see Table 1.
Gastric and Esophageal Cancer represent leading causes of cancer -related deaths globally, in particular in china, but treatment still remain very challenge. All above Lisha Fan, MD therapy’s data were came from “ UFT, Zongjifeng and Huanjingjian, A New Approach to Treat Advanced and Metastatic Solid Tumors” Written by Lisha Fan, MD, Presented this article at Department of Radiation Oncology, Boston University Hospital, Boston, in December, 1989. (The Clinical Trial was Designed & Conducted by Lisha Fan, MD, during the period of 1986-1989, when she was an oncology fellow at Subei Hospital, Jiangsu China.) Esophageal carcinoma is the sixth most common cause of cancer-related death, and 462,000 new cases were diagnosed during 2002 ,… Survival rates are poor with Esophageal Cancer and high incidence in China, but among these 24 cases, there were 2 cases of nasopharyngeal cancer and one Esophageal obtained completed response and survived.
See details here
- Metastatic Breast Cancer
- Therapy Comparison
- Case 1: Esophageal Cancer
- Case 2: Nasopharyngeal Cancer
- Case 3: Nasopharyngeal Cancer
- Case 4: Breast Cancer w/ Liver & Bone Mets.
- Case 5: Breast Cancer w/ Bone Mets.
- Case 6: Extranodal NK’T-cell Lymphoma
- Case 7: Breast Cancer Survival w/ Thyroid Tumors
- Case 8: GBM- Glioblastoma-multiform
- Case 9: Recurrent Adenocystic Carcinoma